Adma Biologics
ADMA on Nasdaq. Adma Biologics sells medicines made from plasma to people with weak immune systems. Market value $3.0bn.
Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $4.55 of spare cash in the past 12 months. A savings account pays about $4.
You pay 12.4 years of operating profit for the business. The average large US company costs around 18.
The filings do not give us enough to work this out.
Quality score: 73 of 100. Price score: 91 of 100. Our list needs 70 on quality and 60 on price.
$13.17 a share, 83% above its 1-year low
Over the past year the price has ranged from $7.21 to $20.46.
Pays no dividend
Prices from Friday’s close (20 November).
Five years of cash, in billions
Spare cash swings from quarter to quarter here: $133 million in the past 12 months, $28 million in the year to December 2025.
| Revenue | |||||
| Revenue | $81m | $154m | $258m | $426m | $510m |
| Operating margin | |||||
| Operating margin | -72.1% | -25.5% | 8.4% | 32.6% | 37.5% |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | n/a | 0.21 | 0.15 |
| Shares outstanding | |||||
| Shares outstanding | 0.20bn | 0.23bn | 0.24bn | 0.24bn | 0.22bn |
Health checks
- Free cash flow positive3 of 5 years
- Accounting looks honest (Beneish)Warning signs
- Financial strength (Piotroski)6 of 9
- Profit backed by cash (accruals)No
- Debt0.15× equity
- Revenue growth, five yearsStrong, 64.6% a year
- Buying back its own sharesNo, 13% more shares since 2021
The quarter to September 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $141 million last quarter, up 5% on a year ago.
- Profit: $50 million, up 37% on a year ago.
- It keeps 46 cents of each $1 of sales as operating profit, up from 34 cents a year earlier.
- Spare cash over the past 12 months: $133 million, up from $41 million.
- 8% fewer shares than a year ago. Each share owns a bit more of the company.
- Debt is $71 million more than cash, up from $11 million a year ago.
- Sales grew on a year ago in 3 of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| December 2024 | $118m |
| March 2025 | $115m |
| June 2025 | $122m |
| September 2025 | $134m |
| December 2025 | $139m |
| March 2026 | $114m |
| June 2026 | $124m |
| September 2026 | $141m |
| Quarter to | Amount |
|---|---|
| December 2024 | $112m |
| March 2025 | $27m |
| June 2025 | $34m |
| September 2025 | $36m |
| December 2025 | $49m |
| March 2026 | $45m |
| June 2026 | $38m |
| September 2026 | $50m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 25 February 2026
- Next quarterly (estimated, 10-Q)
- 3 February 2027
Who owns it
2 long-term investors we follow own it, unchanged from 2 last quarter. 323 funds in all.
- FundsmithTerry Smith
- Value
- $14m
- Share of fund
- 0.1%
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| FundsmithTerry Smith | $14m | 0.1% | |
| Gotham Asset ManagementJoel Greenblatt | $617,949 | <0.1% | New |
Sold out this quarter
- Royce & AssociatesChuck RoyceSold out
Largest holders overall
- BlackRock$321mAdded
- State Street$143mAdded
- Vanguard Capital Management$85m
- Vanguard Portfolio Management$84mAdded
- Rubric Capital Management LP$78mAdded
- Capital Research Global Investors$73mCut
- First Trust Advisors LP$65mAdded
- Geode Capital Management$51mAdded
- Caligan Partners LP$48mAdded
- D. E. Shaw$44mAdded
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
6 investors own more than 5%.
- BlackRock, Inc.Passive investor15.1%Since 31 March 2025
- STATE STREET CORPORATIONPassive investor6.1%−1.3 ptsSince 30 September 2026
- Rubric Capital Management LPPassive investorat least 5.5%(filed with 1 related holder)Since 30 September 2026
- Vanguard Capital ManagementPassive investor5.1%Since 31 March 2026
- SSGA FUNDS MANAGEMENT, INC.Passive investor5.0%Since 30 June 2026
- Invesco Ltd.Passive investor5.0%−0.4 ptsSince 31 December 2025
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
BlackRock, Inc. Passive investor | 15.1% | 31 March 2025 | |
STATE STREET CORPORATION Passive investor | 6.1%−1.3 pts | 30 September 2026 | |
Rubric Capital Management LP Passive investor | at least 5.5% (filed with 1 related holder) | 30 September 2026 | |
Vanguard Capital Management Passive investor | 5.1% | 31 March 2026 | |
SSGA FUNDS MANAGEMENT, INC. Passive investor | 5.0% | 30 June 2026 | |
Invesco Ltd. Passive investor | 5.0%−0.4 pts | 31 December 2025 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 2 insiders bought $468,294 of shares on the open market. 3 sold $3m, $3m of it under preset trading plans.
- Guiheen Lawrence P.DirectorSold
- Date
- 16 November 2026
- Shares
- 10,000
- Price
- $13.92
- Value
- $139,200
- Grossman Adam SPresident and CEO, DirectorSoldunder a preset trading plan
- Date
- 16 November 2026
- Shares
- 21,000
- Price
- $13.72
- Value
- $288,120
- Grossman Adam SPresident and CEO, DirectorSoldunder a preset trading plan
- Date
- 5 November 2026
- Shares
- 147,000
- Price
- $12.00
- Value
- $2m
- Grossman Jerrold BDirectorBought
- Date
- 27 May 2026
- Shares
- 6,400
- Price
- $7.91
- Value
- $50,624
- Grossman Jerrold BDirectorBought
- Date
- 12 May 2026
- Shares
- 12,500
- Price
- $8.01
- Value
- $100,125
- Grossman Jerrold BDirectorBought
- Date
- 11 May 2026
- Shares
- 12,500
- Price
- $8.01
- Value
- $100,125
- Grossman Adam SPresident and CEO, DirectorSoldunder a preset trading plan
- Date
- 16 March 2026
- Shares
- 21,000
- Price
- $15.16
- Value
- $318,360
- Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceSold
- Date
- 9 March 2026
- Shares
- 10,096
- Price
- $15.63
- Value
- $157,800
- ELMS STEVEDirectorBought
- Date
- 6 March 2026
- Shares
- 7,000
- Price
- $15.39
- Value
- $107,730
- ELMS STEVEDirectorBought
- Date
- 5 March 2026
- Shares
- 7,000
- Price
- $15.67
- Value
- $109,690
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 16 November 2026 | Guiheen Lawrence P. Director | Sold | 10,000 | $13.92 | $139,200 |
| 16 November 2026 | Grossman Adam S President and CEO, Director | Sold under a preset trading plan | 21,000 | $13.72 | $288,120 |
| 5 November 2026 | Grossman Adam S President and CEO, Director | Sold under a preset trading plan | 147,000 | $12.00 | $2m |
| 27 May 2026 | Grossman Jerrold B Director | Bought | 6,400 | $7.91 | $50,624 |
| 12 May 2026 | Grossman Jerrold B Director | Bought | 12,500 | $8.01 | $100,125 |
| 11 May 2026 | Grossman Jerrold B Director | Bought | 12,500 | $8.01 | $100,125 |
| 16 March 2026 | Grossman Adam S President and CEO, Director | Sold under a preset trading plan | 21,000 | $15.16 | $318,360 |
| 9 March 2026 | Kestenberg-Messina Kaitlin M. COO and SVP, Compliance | Sold | 10,096 | $15.63 | $157,800 |
| 6 March 2026 | ELMS STEVE Director | Bought | 7,000 | $15.39 | $107,730 |
| 5 March 2026 | ELMS STEVE Director | Bought | 7,000 | $15.67 | $109,690 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
How the boss is paid
Adam S. Grossman was paid $10.2 million in 2025, about 120 times the typical employee’s pay.
The yearly bonus pays for per-share results:
We couldn’t tell from the filing.
The long-term stock award pays for per-share results:
We couldn’t tell from the filing.
Why it matters: new shares can grow total profit while each share earns less. Per-share goals pay the boss only when your slice grows.
From the proxy statement (the company’s yearly voting pack) filed 15 April 2026. Picked out automatically from the company’s own filing. Evidence, not our verdict.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 25 Feb 2026, plus the 10-Q filed 4 Nov 2026 and 7 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
- Its accounts show patterns that sometimes come before companies have to correct past results (Beneish score).
- Profits run ahead of cash.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.